IL253873A0 - Fluorine tetrahydronaphthyridinyl nonanoic acid derivatives and their uses - Google Patents
Fluorine tetrahydronaphthyridinyl nonanoic acid derivatives and their usesInfo
- Publication number
- IL253873A0 IL253873A0 IL253873A IL25387317A IL253873A0 IL 253873 A0 IL253873 A0 IL 253873A0 IL 253873 A IL253873 A IL 253873A IL 25387317 A IL25387317 A IL 25387317A IL 253873 A0 IL253873 A0 IL 253873A0
- Authority
- IL
- Israel
- Prior art keywords
- tetrahydronaphthyridinyl
- fluorinated
- acid derivatives
- nonanoic acid
- nonanoic
- Prior art date
Links
- SBSVVCSSIIMTQL-UHFFFAOYSA-N N1(CCCC2=CC=CN=C12)C(C(=O)O)CCCCCCC Chemical class N1(CCCC2=CC=CN=C12)C(C(=O)O)CCCCCCC SBSVVCSSIIMTQL-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118303P | 2015-02-19 | 2015-02-19 | |
| PCT/US2016/018612 WO2016134223A2 (en) | 2015-02-19 | 2016-02-19 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL253873A0 true IL253873A0 (en) | 2017-10-31 |
Family
ID=56689184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL253873A IL253873A0 (en) | 2015-02-19 | 2017-08-07 | Fluorine tetrahydronaphthyridinyl nonanoic acid derivatives and their uses |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9790222B2 (enExample) |
| EP (2) | EP3925959A1 (enExample) |
| JP (2) | JP2018510139A (enExample) |
| KR (1) | KR102647026B1 (enExample) |
| CN (2) | CN107531699A (enExample) |
| AU (1) | AU2016219906B2 (enExample) |
| BR (1) | BR112017017888A2 (enExample) |
| CA (1) | CA2976634C (enExample) |
| ES (1) | ES2892954T3 (enExample) |
| IL (1) | IL253873A0 (enExample) |
| RU (1) | RU2017132433A (enExample) |
| TW (1) | TWI736529B (enExample) |
| WO (1) | WO2016134223A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014124302A1 (en) | 2013-02-07 | 2014-08-14 | Scifluor Life Sciences, Llc | Fluorinated integrin antagonists |
| US8901144B2 (en) * | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016134223A2 (en) * | 2015-02-19 | 2016-08-25 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| WO2016154369A1 (en) * | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Composition and methods for treating chronic kidney disease |
| KR20170141757A (ko) * | 2015-04-30 | 2017-12-26 | 사이플루어 라이프 사이언시즈, 인크 | 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도 |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| WO2017189828A1 (en) | 2016-04-27 | 2017-11-02 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| EA201991123A1 (ru) | 2016-11-08 | 2019-11-29 | ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV | |
| MA46743A (fr) | 2016-11-08 | 2019-09-18 | Bristol Myers Squibb Co | Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v |
| ES2898835T3 (es) | 2016-11-08 | 2022-03-09 | Bristol Myers Squibb Co | Azol amidas y aminas como inhibidores de la integrina alfav |
| ES2984394T3 (es) | 2016-11-08 | 2024-10-29 | Bristol Myers Squibb Co | Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v |
| AU2017359030A1 (en) | 2016-11-08 | 2019-06-20 | Bristol-Myers Squibb Company | Pyrrole amides as alpha v integrin inhibitors |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| SG11201907820SA (en) | 2017-02-28 | 2019-09-27 | Morphic Therapeutic Inc | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2018183795A1 (en) * | 2017-03-30 | 2018-10-04 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
| US11292802B2 (en) | 2017-11-07 | 2022-04-05 | Bristol-Myers Squibb Company | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors |
| WO2019210200A1 (en) * | 2018-04-27 | 2019-10-31 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
| CA3109534A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibiting .alpha.v .beta.6 integrin |
| EP3843727A4 (en) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
| UY38352A (es) * | 2018-08-29 | 2020-03-31 | Morphic Therapeutic Inc | Inhibidores de integrina alfavbeta6 |
| CN115989235A (zh) * | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
| WO2021231581A1 (en) | 2020-05-12 | 2021-11-18 | Scifluor Life Sciences, Inc. | METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED α V INTEGRIN ANTAGONISTS |
| WO2022087164A1 (en) * | 2020-10-20 | 2022-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Injectable hydrogels for adoptive cell therapy |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307483A4 (en) | 1987-03-30 | 1990-02-06 | Anritsu Corp | LIGHT SIGNAL GENERATOR AND CALIBRATION METHOD OF A LIGHT POWER MEASURING DEVICE WITH THIS LIGHT SIGNAL GENERATOR. |
| CA1318254C (en) | 1988-01-06 | 1993-05-25 | Munehiro Tomikawa | Inhibitory agent of hepatic fibrosis containing pantethine |
| ES2104938T3 (es) | 1991-04-01 | 1997-10-16 | Univ Duke | Metodo de inhibir la fibrosis. |
| US5501969A (en) | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
| JP3818322B2 (ja) | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
| US6544767B1 (en) | 1994-10-27 | 2003-04-08 | Axys Pharmaceuticals, Inc. | Cathespin O2 protease |
| US5736357A (en) | 1994-10-27 | 1998-04-07 | Arris Pharmaceutical | Cathespin O protease |
| US5645839A (en) | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| US6211184B1 (en) | 1996-08-29 | 2001-04-03 | Merck & Co., Inc. | Integrin antagonists |
| AU3215597A (en) | 1996-08-30 | 1998-03-19 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| AU736026B2 (en) | 1997-12-17 | 2001-07-26 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| CN1284955A (zh) | 1997-12-17 | 2001-02-21 | 麦克公司 | 整联蛋白受体拮抗剂 |
| WO1999031061A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6066648A (en) | 1997-12-17 | 2000-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| IL136314A0 (en) * | 1997-12-17 | 2001-05-20 | Merck & Co Inc | Integrin receptor antagonists |
| US6117445A (en) | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
| US6420396B1 (en) * | 1998-12-16 | 2002-07-16 | Beiersdorf Ag | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
| US6677360B2 (en) | 1998-12-16 | 2004-01-13 | Bayer Aktiengesellschaft | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
| US6291503B1 (en) * | 1999-01-15 | 2001-09-18 | Bayer Aktiengesellschaft | β-phenylalanine derivatives as integrin antagonists |
| DK1187592T3 (da) * | 1999-06-02 | 2007-11-05 | Merck & Co Inc | Alfa v-integrinreceptorantagonister |
| US6407241B1 (en) | 1999-11-08 | 2002-06-18 | Merck & Co., Inc. | Process and intermediates for the preparation of imidazolidinone αv integrin antagonists |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| WO2001053297A1 (en) | 2000-01-20 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| WO2001053262A1 (en) | 2000-01-24 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| AU3413401A (en) | 2000-02-22 | 2001-09-03 | Daiichi Asubio Pharma Co., Ltd. | Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
| GB0011817D0 (en) * | 2000-05-16 | 2000-07-05 | Pharmacia & Upjohn Spa | Antagonists of integrin receptors |
| DE60126496T2 (de) | 2000-07-26 | 2007-11-15 | Merck & Co., Inc. | Alpha v integrin-rezeptor-antagonisten |
| AU2001292598B2 (en) | 2000-09-14 | 2006-06-29 | Merck & Co., Inc. | Alpha V integrin receptor antagonists |
| AU2001290772A1 (en) | 2000-09-14 | 2002-03-26 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
| JP2004508401A (ja) | 2000-09-18 | 2004-03-18 | メルク エンド カムパニー インコーポレーテッド | シクロオキシゲナーゼ−２阻害剤およびインテグリンアルファ−ｖアンタゴニストの組合せを用いる炎症の治療 |
| US7074930B2 (en) | 2001-11-06 | 2006-07-11 | Merck & Co., Inc | Amine salts of an integrin receptor antagonist |
| US20040053968A1 (en) | 2001-12-28 | 2004-03-18 | Hartman George D. | Methods and compositions for treating peridontal disease |
| JP2006504696A (ja) | 2002-09-20 | 2006-02-09 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体アンタゴニストのマンニトール製剤 |
| US20050043344A1 (en) | 2002-12-20 | 2005-02-24 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists derivatives |
| JP4912881B2 (ja) * | 2003-10-01 | 2012-04-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗線維症薬としてのαｖβ３及びαｖβ６インテグリンアンタゴニスト |
| WO2009114776A2 (en) * | 2008-03-14 | 2009-09-17 | Visen Medical, Inc. | Integrin targeting agents and methods of using same |
| WO2011060395A1 (en) | 2009-11-16 | 2011-05-19 | Schering Corporation | Cyclic ureas useful as hiv inhibitors |
| CA2800618C (en) | 2010-05-26 | 2018-08-28 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| WO2012154894A2 (en) | 2011-05-09 | 2012-11-15 | Allegro Pharmaceuticals, Inc. | Integrin receptor antagonists and their methods of use |
| CA2840491A1 (en) | 2011-06-28 | 2013-01-03 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing sorafenib |
| US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| WO2014124302A1 (en) * | 2013-02-07 | 2014-08-14 | Scifluor Life Sciences, Llc | Fluorinated integrin antagonists |
| WO2016134223A2 (en) * | 2015-02-19 | 2016-08-25 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| KR20170141757A (ko) | 2015-04-30 | 2017-12-26 | 사이플루어 라이프 사이언시즈, 인크 | 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도 |
| WO2018183795A1 (en) | 2017-03-30 | 2018-10-04 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
-
2016
- 2016-02-19 WO PCT/US2016/018612 patent/WO2016134223A2/en not_active Ceased
- 2016-02-19 CN CN201680022826.5A patent/CN107531699A/zh active Pending
- 2016-02-19 CA CA2976634A patent/CA2976634C/en active Active
- 2016-02-19 ES ES16753120T patent/ES2892954T3/es active Active
- 2016-02-19 TW TW105104964A patent/TWI736529B/zh not_active IP Right Cessation
- 2016-02-19 EP EP21171386.2A patent/EP3925959A1/en not_active Withdrawn
- 2016-02-19 US US15/047,717 patent/US9790222B2/en not_active Expired - Fee Related
- 2016-02-19 AU AU2016219906A patent/AU2016219906B2/en not_active Ceased
- 2016-02-19 CN CN202210129062.7A patent/CN114805342A/zh active Pending
- 2016-02-19 KR KR1020177026258A patent/KR102647026B1/ko active Active
- 2016-02-19 BR BR112017017888A patent/BR112017017888A2/pt not_active Application Discontinuation
- 2016-02-19 RU RU2017132433A patent/RU2017132433A/ru not_active Application Discontinuation
- 2016-02-19 EP EP16753120.1A patent/EP3259271B1/en active Active
- 2016-02-19 JP JP2017544035A patent/JP2018510139A/ja active Pending
-
2017
- 2017-08-07 IL IL253873A patent/IL253873A0/en active IP Right Grant
- 2017-09-11 US US15/700,351 patent/US10301307B2/en active Active
-
2019
- 2019-04-03 US US16/373,780 patent/US20190225609A1/en not_active Abandoned
-
2020
- 2020-10-12 JP JP2020171641A patent/JP7191299B2/ja active Active
- 2020-10-22 US US17/076,891 patent/US11685738B2/en active Active
-
2023
- 2023-05-31 US US18/203,776 patent/US12286432B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017132433A3 (enExample) | 2019-03-25 |
| JP2021008511A (ja) | 2021-01-28 |
| ES2892954T3 (es) | 2022-02-07 |
| CN114805342A (zh) | 2022-07-29 |
| RU2017132433A (ru) | 2019-03-19 |
| US20210277000A1 (en) | 2021-09-09 |
| US20190225609A1 (en) | 2019-07-25 |
| US10301307B2 (en) | 2019-05-28 |
| US12286432B2 (en) | 2025-04-29 |
| WO2016134223A2 (en) | 2016-08-25 |
| US20170369490A1 (en) | 2017-12-28 |
| TW201643161A (zh) | 2016-12-16 |
| BR112017017888A2 (pt) | 2018-04-10 |
| TWI736529B (zh) | 2021-08-21 |
| CA2976634C (en) | 2023-10-17 |
| JP7191299B2 (ja) | 2022-12-19 |
| WO2016134223A3 (en) | 2016-10-20 |
| AU2016219906B2 (en) | 2020-10-01 |
| US9790222B2 (en) | 2017-10-17 |
| CN107531699A (zh) | 2018-01-02 |
| JP2018510139A (ja) | 2018-04-12 |
| US20160244447A1 (en) | 2016-08-25 |
| EP3925959A1 (en) | 2021-12-22 |
| EP3259271B1 (en) | 2021-05-05 |
| EP3259271A4 (en) | 2018-07-11 |
| KR20170117578A (ko) | 2017-10-23 |
| KR102647026B1 (ko) | 2024-03-12 |
| US20240092775A1 (en) | 2024-03-21 |
| US11685738B2 (en) | 2023-06-27 |
| EP3259271A2 (en) | 2017-12-27 |
| CA2976634A1 (en) | 2016-08-25 |
| AU2016219906A1 (en) | 2017-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3259271A4 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| ZA201607773B (en) | Cyclopropanamine compound and use thereof | |
| SG10202106970XA (en) | Stable anti-ifnar1 formulation | |
| IL255054A0 (en) | Tetrahydronephthyridinyl propionic acid derivatives and their uses | |
| IL259646A (en) | Formulations with reduced polysorbate dissolution | |
| IL264539A (en) | The composition soothes locally for an extended period of time | |
| GB201419091D0 (en) | Formulations | |
| GB201514758D0 (en) | Formulation | |
| GB201522311D0 (en) | Use | |
| GB201522309D0 (en) | Use | |
| ES2873376T5 (en) | Maropitant formulation | |
| PL3307053T3 (pl) | Nagarniacz teleskopowy | |
| GB201521085D0 (en) | Use | |
| GB2536277B (en) | An extendible tripod leg | |
| GB201521771D0 (en) | Formulation | |
| GB201518466D0 (en) | Use | |
| GB201510077D0 (en) | Use | |
| GB201509891D0 (en) | Formulation | |
| HK1241361A1 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| GB201522443D0 (en) | Use | |
| GB201522411D0 (en) | Use | |
| GB201514770D0 (en) | Compounds and their use | |
| GB201515987D0 (en) | Use | |
| GB201514014D0 (en) | Formulation | |
| GB201504662D0 (en) | Formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |